Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Pushpendra Goswami, PhD MSc, BPharm, Tatiana Ionova, DSc, Esther Natalie Oliva, PhD, Roger Else, Jonathan Kell, MD, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Daniel Jennings, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Stewart McConnell, Catherine Langton, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2019) 134 (Supplement_1): 3484.

https://doi.org/10.1182/blood-2019-129030

Published: 2019

Journal Articles

A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL

Blood (2018) 132 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2018-99-112162

Published: 2018

Journal Articles

An Ongoing Peer Review Programme for Paediatric and Adult Haemoglobinopathy (HbO) Services in England Drives Improvements in Care

Jo Howard, Josh Wright, MD, Banu Kaya, MD, Subarna Chakravorty, MD PhD, Jane Eminson

Blood (2016) 128 (22): 3526.

https://doi.org/10.1182/blood.V128.22.3526.3526

Published: 2016

Journal Articles

Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation

Pushpendra Goswami, B.Pharmacy, MSc, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Jonathan Kell, MD, Saad Al-Ismail, MD, Esther Oliva, MD, Tatyana Ionova, PhD, Roger Else, Marina Karakantza, MD, Daniel Jennings, Anita Waldmann

Blood (2016) 128 (22): 5985.

https://doi.org/10.1182/blood.V128.22.5985.5985

Published: 2016

Journal Articles

Risk Factors for Recurrent CMV Reactivation in CMV Seropositive Recipients Following T Cell Depleted Haematopoietic Stem Cell Transplantation

Abeer Ibrahim, Wendy Ingram, Nicola Price, David Davies, Keith Wilson

Blood (2014) 124 (21): 1134.

https://doi.org/10.1182/blood.V124.21.1134.1134

Published: 2014

Journal Articles

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Nagendra Mogasala, Sumana Devata, MD, Anthony Perissinotti, PharmD, Dale Bixby, MD PhD

Blood (2014) 124 (21): 2297.

https://doi.org/10.1182/blood.V124.21.2297.2297

Published: 2014

Journal Articles

Retrospective Study Of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma

Radha Raghupathy, MD, Sabarish Ayyappan, MD, Dhivya Prabhakar, MD, Frankie KF Mo, Erica L. Campagnaro, MD, Kenny Ieng Kit Lei, MD, FRCP

Blood (2013) 122 (21): 1121.

https://doi.org/10.1182/blood.V122.21.1121.1121

Published: 2013

Journal Articles

Low Yield From Hepatitis C Virus (HCV) Lookback At a Large Cancer Center

Matthew T. Whitehurst, MD, Kaaron Benson, MD

Blood (2013) 122 (21): 4821.

https://doi.org/10.1182/blood.V122.21.4821.4821

Published: 2013

Journal Articles

Anti-Myeloma Effects of Carfilzomib with Cyclophosphamide (CY) or Bendamustine (Ben).

Eric Sanchez, Mingjie Li, Cathy Wang, Haiming Chen, MD., Ph.D, James R. Berenson, MD

Blood (2012) 120 (21): 2952.

https://doi.org/10.1182/blood.V120.21.2952.2952

Published: 2012

Journal Articles

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid ® Treatment Continuation Scheme™ (TCS)

Cathy D. Williams, MBBS, MCRP, FRCPath, Mathew Simcock, MSc, Imran Lodhi, MBBS, Suzanne K. Robinson, PhD, Faith E. Davies, MD

Blood (2012) 120 (21): 4067.

https://doi.org/10.1182/blood.V120.21.4067.4067

Published: 2012

Journal Articles

Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,

Stephen Schey, MD, Sean Stern, Sujith Dhanasiri, Ruth Brown, MS, MHSA

Blood (2011) 118 (21): 4181.

https://doi.org/10.1182/blood.V118.21.4181.4181

Published: 2011

Journal Articles

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

Richard J Kelly, MBChB, MRCP(UK), FRCPath, Anita Hill, MBChB, MRCP(UK), FRCPath, PhD, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Stephen John Richards, PhD, FRCPath, Louise M Arnold, RN, BSc, hons, Gemma L Valters, RN, BSc, hons, Matthew Cullen, MSc, Dena R Cohen, MSc, Walter M Gregory, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 639.

https://doi.org/10.1182/blood.V116.21.639.639

Published: 2010

Journal Articles

Clinical Outcomes with the LMWH, Tinzaparin (Innohep®) in Pregnancy. An International Retrospective Audit..

Marc Rodger, MD, MSc, Cathy Nelson-Piercy, Raymond Powrie, Jeanne-Yvonne Borg, Ian Greer

Blood (2009) 114 (22): 487.

https://doi.org/10.1182/blood.V114.22.487.487

Published: 2009

Journal Articles

First Report of National Estimates of the Incidence of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders from the U.S. SEER Program.

Dana E. Rollison, PhD, Matthew Hayat, PhD, Martyn Smith, PhD, Sara S. Strom, PhD, William D. Merritt, PhD, Lynn Ries, MS, Brenda K. Edwards, PhD, Alan F. List, MD

Blood (2006) 108 (11): 247.

https://doi.org/10.1182/blood.V108.11.247.247

Published: 2006

Journal Articles

Impact of Age and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin’s Lymphoma Diagnosed in England and Wales.

Julia Bohlius, Bernard Rachet, Andreas Engert, Michel Coleman

Blood (2006) 108 (11): 346.

https://doi.org/10.1182/blood.V108.11.346.346

Published: 2006

Journal Articles

Severe Sideroblastic Anaemia in an ALAS2 Compound Heterozygote for −206G, a Common Polymorphism, and a Novel Mutation in Exon 11 (Lys535del) Linked to Lack of Haemoglobinisation In Vitro and Ineffective Erythropoiesis In Vivo.

Alison May, PhD, Carol Barton, FRCPath, Gillian Masters, MA, Jeanne Kingston, BSc, Sue Lawless, MSc, Michael Jenner, MRCPath

Blood (2005) 106 (11): 3541.

https://doi.org/10.1182/blood.V106.11.3541.3541

Published: 2005

Journal Articles

Trends and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin’s Lymphoma Diagnosed in England and Wales between 1986 and 1999.

Julia Bohlius, MD, MScPH, Bernard Rachet, MD, PhD, Ellen Nolte, MSc, PhD, Andreas Engert, MD, Michel Coleman, MSc

Blood (2005) 106 (11): 749.

https://doi.org/10.1182/blood.V106.11.749.749

Published: 2005

NARROW

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL

An Ongoing Peer Review Programme for Paediatric and Adult Haemoglobinopathy (HbO) Services in England Drives Improvements in Care

Development of a Novel Patient-Reported Outcome Measure in Haematological Malignancy for Use in Routine Clinical Practice: Item Generation

Risk Factors for Recurrent CMV Reactivation in CMV Seropositive Recipients Following T Cell Depleted Haematopoietic Stem Cell Transplantation

Clinical Availability of All-Trans Retinoic Acid (ATRA) for Patients with Suspected Acute Promyelocytic Leukemia – Why National Guidelines May Not be Followed

Retrospective Study Of Incidence Of Thromboses In Chinese Versus African Americans With Multiple Myeloma

Low Yield From Hepatitis C Virus (HCV) Lookback At a Large Cancer Center

Anti-Myeloma Effects of Carfilzomib with Cyclophosphamide (CY) or Bendamustine (Ben).

Experience with Long-Term Lenalidomide (LEN) Treatment in the Clinical Setting: Results From the UK Revlimid ® Treatment Continuation Scheme™ (TCS)

Cost-Effectiveness of Lenalidomide in Multiple Myeloma Patients with 1 Prior Therapy in England and Wales,

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

Clinical Outcomes with the LMWH, Tinzaparin (Innohep®) in Pregnancy. An International Retrospective Audit..

First Report of National Estimates of the Incidence of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders from the U.S. SEER Program.

Impact of Age and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin’s Lymphoma Diagnosed in England and Wales.

Severe Sideroblastic Anaemia in an ALAS2 Compound Heterozygote for −206G, a Common Polymorphism, and a Novel Mutation in Exon 11 (Lys535del) Linked to Lack of Haemoglobinisation In Vitro and Ineffective Erythropoiesis In Vivo.

Trends and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkin’s Lymphoma Diagnosed in England and Wales between 1986 and 1999.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only